Ivan Cornella-Taracido

Ivan Cornella-Taracido is the Chief Scientific Officer and Co-Founder of Covant Therapeutics, where he leads the scientific strategy to advance target enablement and drug discovery for novel oral therapeutics. With over 20 years of experience in pharmaceutical research, Ivan has held leadership roles at Roivant Sciences, Cedilla Therapeutics, Merck, AstraZeneca, Sanofi, and Novartis. Ivan holds a Ph.D. in Chemistry from Universidade da Coruña, Spain, and completed postdoctoral fellowships at Harvard Medical School and Boston College, along with executive training at MIT Sloan. A recognized innovator in drug discovery, he consults for biotech and pharma. As active member of several professional science organizations, Ivan volunteers mentoring junior scientists and students, and is a frequent speaker at international scientific forums.